Candel Therapeutics, Inc.

CADL · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
116
SEC Filings

Business Summary

PART I . Overview We are a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Our engineered viruses are designed to induce a systemic anti-tumor response due to induction of immunogenic cell death within the tumor microenvironment, thus releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. This is inte...

Next Earnings

Q2 FY2026 — expected 2026-08-17

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionCADLdiscussed_in_filing Cybersecurity
topic_mentionCADLdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-122025-12-310001193125-26-103134EDGAR125K words
2025-03-132024-12-310000950170-25-038803EDGAR—
2024-03-282023-12-310000950170-24-037637EDGAR—
2023-03-302022-12-310000950170-23-010760EDGAR—
2022-03-292021-12-310000950170-22-004857EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-132025-09-300001193125-25-279086EDGAR81K words
2025-08-142025-06-300000950170-25-108450EDGAR—
2025-05-132025-03-310000950170-25-069833EDGAR—
2024-11-142024-09-300000950170-24-126767EDGAR—
2024-08-132024-06-300000950170-24-095784EDGAR—
2024-05-142024-03-310000950170-24-059118EDGAR—
2023-11-092023-09-300000950170-23-061566EDGAR—
2023-08-102023-06-300000950170-23-040984EDGAR—
2023-05-112023-03-310000950170-23-020873EDGAR—
2022-11-102022-09-300000950170-22-024197EDGAR—
2022-08-052022-06-300000950170-22-014970EDGAR—
2022-05-122022-03-310000950170-22-009479EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-120001193125-26-103126EDGAR3K words
2026-02-230001193125-26-062490EDGAR—
2026-02-190001193125-26-059334EDGAR—
2025-12-050001193125-25-308719EDGAR—
2025-11-130001193125-25-279072EDGAR—
2025-10-140001193125-25-238254EDGAR—
2025-08-210000950170-25-110682EDGAR—
2025-08-140000950170-25-108448EDGAR—
2025-06-240001193125-25-145405EDGAR—
2025-06-230001193125-25-144204EDGAR—

116 total filings indexed. 89 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001841387
TickerCADL
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 1b21d3bd03e19708bd105cd0ff1aab054132889698815432bd38cf9f6d5239f2
parent: 671784c52a3ae442489ad5bd8673436c0ffd48cb3072978ef362f6e883a0bf58
content hash: 29f5669a8b405cd301061ada96c90adc481b1692707af06db83497d2e5dfa88c
signed: 2026-04-13T04:44:10.685Z
sources: 17 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf